FDA Inspection 1009153 — Karyopharm Therapeutics Inc.
The FDA completed an inspection of Karyopharm Therapeutics Inc. on February 8, 2017 in Newton, MA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- February 8, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Newton, MA (United States)
Additional Details
Sponsor, Contract Research Organization